▶ Watch on YouTube
Health

FDA approves weekly Sogroya injection for children with Turner syndrome

2026-11-20 · Nuevo Día
FDA approves weekly Sogroya injection for children with Turner syndrome

The U.S. Food and Drug Administration (FDA) approved on Friday the weekly Sogroya (somapacitan-beco) injection for children aged 2 and a half and older with growth failure associated with Turner syndrome, pharmaceutical company Novo Nordisk announced.

Sogroya is the first and only long-acting growth hormone approved for this population with a single weekly dose, as an alternative to the daily injections these patients had received until now. It is the fifth pediatric growth-related use authorized for this medicine.

The approval was based on the REAL8 study, a phase 3 trial that included 105 children aged 2.5 to 10 who had not previously received growth hormone treatment. At 52 weeks, average growth velocity was 8.9 centimeters per year with Sogroya, compared with 9.7 with daily somatropin.

According to Novo Nordisk, the weekly regimen offers 313 days a year without injections. The most common adverse reactions were respiratory infections, fever, diarrhea, vomiting, and injection-site reactions.

Photo: Securities.io

Source: Securities.io

← More news in Health · Leer en español